HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging men, the impact of...

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and both dementia and...

Agent Orange Exposure Not Associated With Worse PC Outcomes

MADISON, WI—How does a history of Agent Orange exposure affect prostate cancer survival in VA patients receiving androgen deprivation therapy for advanced prostate cancer? That was the question addressed in a Journal of Urology study.1 University of Wisconsin School...

Oral Cancer Therapies Create Critical Demand for Pharmacists

CHICAGO—The pace of U.S. Food and Drug Administration approval of oral anticancer medications has rapidly increased, from less than one a year at the turn of the century to 10 in 2018. While patients generally prefer taking oncolytics by mouth at home to intravenous...

Cancer Trials Boom in VA’s New England Region

Cancer Trials Boom in VA’s New England Region

The number of clinical trials open to veterans with cancer in the New England region (VISN 1) grows every week, leading a return to the prominence the VA had in trial programs in decades past and offering veterans access to the “gold standard” of treatment in oncology.

Factors Affecting Biochemical Recurrence of Prostate Cancer

DURHAM, NC—What is the association between lowest prostate-specific antigen (PSA) and time to nadir with biochemical recurrence (BCR) risk after radical prostatectomy (RP)? A study published recently in the journal Urology used the SEARCH database to try to answer...

Visceral Metastases Predict Overall PC Survival in Veterans

DURHAM, NC—Visceral metastases (VMs) are generally believed to predict worse prognoses compared with bone and lymph metastases in men with metastatic castration-resistant prostate cancer (mCRPC). Still, a new study published in the journal European Urology Focus...

U.S. Medicine Archives

U.S. Medicine Supplements

CE Credits